



**AYRTON DRUG MANUFACTURING LTD**  
**Un-Audited Statement of Financial Position**  
**For the period ending 30th September, 2018**

		30/09/2018	30/09/2017
	Notes	GHC	GHC
<b>Non current assets</b>			
Property, plant and equipment	3	6,893,922	6,696,200
Prepaid lease and land		362,368	371,082.10
Intangible		-	8,950
Deferred tax assets		210,893	-
		<u>7,467,183</u>	<u>7,076,232</u>
<b>Current assets</b>			
Inventories	4	10,721,312	11,403,738
Trade and other receivable	5	14,588,328	10,245,683
Amount due from Associated company		4,904,867	-
Current taxation		-	2,638,198
Cash and bank	6	1,182,992	300,436
<b>Total Current Assets</b>		<u>31,397,499</u>	<u>24,588,055</u>
<b>TOTAL ASSETS</b>		<u>38,864,682</u>	<u>31,664,287</u>
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
Issued capital		4,475,000	4,475,000
Other capital reserve		1,739,436	1,739,436
Income surplus		16,815,182	12,748,970
		<u>23,029,618</u>	<u>18,963,406</u>
<b>Non-current liabilities</b>			
Deferred tax Liability		-	<u>154,459</u>
<b>Current liabilities</b>			
Trade and other payable	7	8,706,571	4,394,574
Amount due to Associated company		-	1,036,406
Income tax payable		602,995	364,798
Short term borrowings	8	6,525,498	6,750,644
<b>Total Liabilities</b>		<u>15,835,064</u>	<u>12,700,881</u>
<b>TOTAL EQUITY AND LIABILITIES</b>		<u>38,864,682</u>	<u>31,664,287</u>

  
 \_\_\_\_\_  
 Director  
 Daniel Apegyei Kissi

  
 \_\_\_\_\_  
 Director  
 Nik Amarteifio

**AYRTON DRUG MANUFACTURING LTD**  
**Un-Audited Statement of Comprehensive Income**  
**For the Period ending 30th September, 2018**

		30/09/2018	30/09/2017
	Notes	GHC	GHC
Revenue		6,566,028	9,003,091
Cost of sales	9	(2,510,182)	(4,244,877)
<b>Gross profit</b>		<b>4,055,846</b>	<b>4,758,214</b>
Other income	10	5,794	-
Exchange (Loss)/Gain		(156,211)	-
Selling and distribution costs	11	(669,218)	(931,207)
Administrative expenses	12	(2,305,887)	(2,180,262)
<b>Operating (Profit)/loss</b>		<b>930,324</b>	<b>1,646,745</b>
Finance income		-	-
Interest Expense	13	(342,793)	(423,142)
<b>(Profit)/loss before tax</b>		<b>587,531</b>	<b>1,223,603</b>
Income tax expense		(203,081)	(287,395)
<b>(Profit)/loss after tax</b>		<b>384,450</b>	<b>936,208</b>
Earnings per share		0.0018	0.0044

